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Background: An intention-to-treat analysis of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial
showed that in patients with severe lower limb ischemia (SLI) due to infrainguinal disease who survived for 2 years after
intervention, initial randomization to a bypass surgery (BSX)-first vs balloon angioplasty (BAP)-first revascularization
strategy was associated with improvements in subsequent overall survival (OS) and amputation-free survival (AFS) of
about 7 and 6 months, respectively. This study explored the value of baseline factors to estimate the likelihood of survival
to 2 years for the trial cohort (Cox model) and for individual BASIL trial patients (Weibull model) as an aid to clinical
decision making.
Methods:Of 452 patients presenting to 27United Kingdom hospitals, 228 were randomly assigned to a BSX-first and 224
to a BAP-first revascularization strategy. Patients were monitored for at least 3 years. Baseline factors affecting the
survival of the entire cohort were examined with a multivariate Cox model. The chances of survival at 1 and 2 years for
patients with given baseline characteristics were estimated with a Weibull parametric model.
Results: At the end of follow-up, 172 patients (38%) were alive without major limb amputation of the trial leg, and 202
(45%) were alive. Baseline factors that were significant in the Cox model were BASIL randomization stratification group,
below knee Bollinger angiogram score, body mass index, age, diabetes, creatinine level, and smoking status. Using these
factors to define five equally sized groups, we identified patients with 2-year survival rates of 50% to 90%. The factors that
contributed to the Weibull predictive model were age, presence of tissue loss, serum creatinine, number of ankle pressure
measurements detectable, maximum ankle pressure measured, a history of myocardial infarction or angina, a history of
stroke or transient ischemia attack, below knee Bollinger angiogram score, body mass index, and smoking status.
Conclusions: Patients in the BASIL trial were at high risk of amputation and death regardless of revascularization strategy.
However, baseline factors can be used to stratify those risks. Furthermore, within a parametricWeibull model, certain of these
factors can be used to help predict outcomes for individuals. It may thus be possible to define the clinical and anatomic
(angiographic) characteristics of SLI patients who are likely—and not likely—to live for >2 years after intervention. Used
appropriately in the context of the BASIL trial outcomes, this may aid clinical decision making regarding a BSX- or BAP-first
revascularization strategy in SLI patients like those randomized in BASIL. (J Vasc Surg 2010;51:52S-68S.)Severe leg ischemia (SLI), characterized by rest/night
pain and tissue loss (ulceration, gangrene), leads to signif-
icant morbidity and mortality and to the consumption of
considerable health care and social care resources in devel-
oped and in developing countries.1 The Bypass versus
Angioplasty in Severe Ischaemia of the Leg (BASIL) trial
remains the only multicenter, randomized controlled trial
(RCT) to compare a bypass surgery (BSX) first with a
balloon angioplasty (BAP) first revascularization strategy in
patients with SLI due to infrainguinal disease.
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(OS) out to 2 years from randomization, although BSX had
significantly more morbidity and was about one-third more
expensive in the short-term.2 However, for those patients
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3.1 years (range, 1-5.7 years).3 Hospital costs and health-
related quality of life (HRQOL) were not significantly
between the two groups during the first 3 years.4
These data suggest that patients like those randomized
in the BASIL trial and who are expected to live 2 years
should usually be considered for BSX rather than BAP.
Conversely, BASIL-like patients not expected for survive
2 years appear to benefit more from a BAP-first strategy
because, in the short-term (2 years), surgery is signifi-
cantly more morbid and expensive.
These data and interpretations have been discussed at
length among the trial investigators and participants. They
have also been presented at meetings to numerous groups
of vascular surgeons and interventionalists from many dif-
ferent countries. Many of these clinicians have made it
known to the investigators that they would value an analysis
of the data that attempts to predict survival for the entire
BASIL cohort as well as for individual BASIL patients
determined from robust (objective) baseline variables that
are easily and widely available in day-to-day clinical practice
at the point of clinical decision making with respect to
pursuing a BSX-first or BAP-first strategy for their patients.
We agree that given the key clinical messages to ema-
nate from the BASIL trial, it is entirely logical to try to
model the factors that might predict whether such patients
might survive for 2 years after randomization. However,
such modelling is fraught with methodologic and interpre-
tational challenges, and any estimates of survival so pro-
duced must be used with great care and in the context of
the overall clinical situation for each patient.
Notwithstanding those important caveats, the specific
aim of this article is to report the results of a study that
examined whether unambiguous, easily obtainable baseline
data could be used tomake informed judgments about how
long a BASIL-like patient is likely to live; and, specifically,
how likely the patient is to survive2 years, which appears
to be the point where the relative merits of a BAP-first and
BSX-first revascularization strategy change.
METHODS
All patients who participated provided written in-
formed consent, and the study was approved by the Multi-
center Research Ethics Committee (MREC) for Scotland.
The BASIL trial was registered with the National Research
Register (NRR) and the International Standard Random-
ised Controlled Trials Number (ISRCTN) Scheme (Num-
ber 45398889; http://www.controlled-trials.com/
ISRCTN45398889/45398889).
Overview of trial methods and collection of
follow-up (death) data. The BASIL trial methods have
been published elsewhere.2,3 Briefly, between August 1999
and June 2004, consultant vascular surgeons and interven-
tional radiologists in 27 United Kingdom (UK) hospitals
randomized 452 patients to a BSX-first or a BAP-first
revascularization strategy. Inclusion criteria were patients
who required revascularization because of SLI, defined as
rest pain or tissue loss from ulcer or gangrene, or both, ofarterial etiology present for 2 weeks. Patients’ diagnostic
imaging had to show a pattern of disease that, in the
consultants’ joint opinion, could equally well be treated by
infrainguinal BSX or BAP.
Randomization was stratified by center and then into
four groups by clinical presentation of rest pain only vs
tissue loss and ankle pressure of 50 vs 50 mm Hg;
namely, (A) rest pain only, 50 mm Hg; (B) rest pain
only,50 mmHg; (C) tissue loss,50 mmHg; and (D)
tissue loss 50 mm Hg. Preintervention angiograms
were scored using the Bollinger method and the Trans-
Atlantic Inter-Society Consensus (TASC) II classifica-
tion system.5
Centers were encouraged to undertake the allocated
procedure as soon as possible after randomization. The
responsible consultant vascular surgeons and interventional
radiologists were permitted to use their preferred tech-
niques, equipment, and graft material as for their normal
practice.
Details of patients recruited in Scottish centers were
logged with the Information and Statistics Division of the
National Health Service in Scotland. Data were gathered
from interrogation of hospital paper and electronic records
and from contacts with general practitioners. In addition,
this prospectively gathered information was crosschecked
by reviewing all available hospital case notes of trial patients
at the end of the study. The status of all patients alive at the
end of follow-up was confirmed by linkage to General
Registry Office (Scotland) or the Office of National Statis-
tics (England) death records. Hospital admissions for Scot-
tish patients were obtained by record linkage to Scottish
Morbidity Records.
The clinical end points were major AFS, defined as a
patient alive without amputation of the trial leg at tran-
stibial level or higher, and OS. Angiograms were scored
according to the Bollinger method (infrainguinal seg-
ments) and the TASC II criteria.1 Details of the angiogram
scoring are the subject of a further report.5
Statistical analysis. For the survival analyses, patients
with no clinical report of survival were taken as censored at
end February 2007 if their survival information was from
the Information and Statistics Division, at end July 2007 if
their death information was from the Office of National
Statistics, or at the date of last clinical contact if it was after
this date. In addition, four patients who were lost to
follow-up and whose deaths investigators thought were
unlikely to have been recorded in the UK were censored at
their last follow-up times; all 1 year 1 month of random-
ization.
The patient-specific clinical and anatomic (angio-
graphic) variables specified as covariates in the trial protocol
were entered into univariate and multivariate analyses with
a Cox proportional hazards model using all available
follow-up data (range, 3-7 years of follow-up).
To predict how a future patient might behave in terms
of overall survival up to 2 years from randomization, a
parametric survival model was developed using a regression
approach based on the Weibull distribution as imple-
ed. T
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to 2 years from randomization was used, with all survivors
beyond this time censored at 2 years.
The regression model used the baseline covariates de-
fined in the protocol to predict survival and also a further
set of four measures that were considered likely to affect
overall survival. The additional measures were a history of
angina or myocardial infarction (MI), history of transient
ischemic attack (TIA) or stroke, the number of ankle pres-
sure measurements that could be obtained (range, 0-3),
and the maximum ankle pressure obtained as a continuous
variable. The latter two variables provided more informa-
tion on the ankle pressures than the simple dichotomy of
ankle pressure higher or lower than 50 mm Hg that was
specified in the protocol. The regression model was simpli-
fied by dropping certain variables using a combination of
backward selection and informed choice, taking note of the
plausibility of the directions of the associations in the data.
This approach runs the risk of over-fitting the model,
which has the effect of making the predictions more ex-
treme than are justified by the data. To overcome this, the
model was developed on a training data set that consisted of
a randomly selected 75% of the original data. A shrinkage
Fig 1. Amputation-free survival, the primary end poin
presented as (A) survival curves and (B) as smoothed esti
on the survival curve indicate that an observation is censor
Table I. Number of and total follow-up time to major am
between randomization and 2 years and after 2 years from
Follow-up period
Patients with amputation of
trial leg or death from any caus
with trial leg intact, No.
Randomization to 2 years 172
2 years from randomization 108
AFS, Amputation-free survival; OS, overall survival.factor was then calculated that corrects for over-fitting, andthe predictions were validated on the remaining 25% of the
data.
A Weibull parametric survival model has a hazard func-
tion that can increase or decrease with time from random-
ization. The model estimates a shape parameter and a linear
predictor that together can be used to calculate the pre-
dicted survival to a given time for any combination of
baseline characteristics. Specifically, the probability of sur-
viving to time t can be written as
S(t) {[t exp]s},
where s is the shape parameter and  is a linear predictor
calculated from the baseline characteristics. A shape param-
eter of 1.0 gives a model with constant hazard (exponential
distribution of survival times), whereas a shape parameter
1.0 indicates a hazard that is decreasing over the follow
up period.
RESULTS
Deaths and amputations before and after 2 years.
To place the predictive analyses in context, the numbers
of deaths and major amputations of the trial leg (the
primary end point for the trial) before and after 2 years
P), and overall survival for the BASIL trial cohort are
of the hazard functions for each event. The vertical lines
he x axis on A and B is time from randomization in years.
tions of trial leg or deaths, or both, from any cause
omization
Total years of follow-up
to this end point (AFS)
Patients with death
from any cause, No.
Total years of
follow-up to
death (OS)
658 131 736
734 119 863t (PE
matesputa
rand
efrom randomization are reported in Table I. Fig 1, A
ety Co
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BASIL trial cohort. After the first 1 to 2 years of follow-
up, the two survival curves are fairly parallel, indicating
that few new amputations occurred at this length of time
from randomization. This is clearer in the smoothed
estimates of the hazard functions (Fig 1, B), which shows
that amputations in the first 1.5 years increase the pri-
mary end point hazard (AFS) compared with that for
death only, but few extra amputations occur after that
time to increase the hazard of the primary end point
(AFS) compared with death. Note also that the initially
high hazard declines during the first 2 years and appears
to become fairly constant after the first 2 years, or
perhaps slightly sooner. This reducing risk is shown by
the numbers of amputations during follow-up: 61, 5, 7,
Table II. Hazard ratios from Cox proportional hazards m
randomization
Variable No.
Randomization stratification group
Tissue loss, ankle pressure 50 mm Hg (C) 222
Ankle pressure 50 mm Hg (B & D) 137
No tissue loss, ankle pressure 50 mm Hg (A) 93
Serum creatinine (log values), mmol/L
Low (4.466) 148
High (4.7274) 143
Missing 21
Medium (4.466-4.7274) 140
Body mass index, kg/m2
Underweight (20) 51
Overweight (25) 115
Obese and severely obese (30) 53
Missing 85
Desirable range (20-25) 148
Diabetic, type 1 and 2 together; yes vs no 190
Age group, y
70-79 193
80 112
70 147
Smoking
Exsmoker 199
Current smoker 164
Nonsmoker 89
Statin 152
Bollinger angiogram score (below knee)
5-8 131
8 129
Missing 34
5 158
Bollinger angiogram score (above knee)
5-8 165
8 119
Missing 34
5 134
TASC group
C 186
B 122
A best 12
Missing 39
D (worst) 93
CI, Confidence interval; HR, hazard ratio; TASC, TransAtlantic Inter-Soci3, and 3 in years 1 to 5, respectively.Relationship between survival to 2 years and base-
line clinical factors (Cox model ). The results of the Cox
proportional hazard models for death from any cause (OS)
during the period up to 2 years from randomization are
reported in Table II for the covariates defined in the orig-
inal trial protocol. Because the baseline variables are corre-
lated, the coefficients change in the multivariate model.
The baseline factors that remained significant in the multi-
variate Cox model were in descending order of their signif-
icance in the multivariate model:
● BASIL randomization stratification group
● Below-knee Bollinger angiogram scores5
● Body mass index
● Age
of time to death during the first 2 years after
Univariate analysis Multivariate analysis
R (95% CI) P HR (95% CI) P
42 (1.29-4.55) .001 1.88 (0.98-3.60) .01
62 (1.92-6.85) 2.56 (1.30-5.04)
61 (0.99-2.62) .005 1.73 (1.05-2.87) .02
24 (1.4-3.59) 2.01 (1.25-3.25)
28 (0.48-3.39) 1.79 (0.66-4.9)
45 (0.85-2.5) .065 1.47 (0.84-2.58) .32
79 (0.49-1.29) 0.96 (0.58-1.59)
59 (0.29-1.2) 0.66 (0.32-1.35)
26 (0.78-2.02) 1.18 (0.72-1.92)
26 (0.88-1.78) .196 1.24 (0.83-1.84) .28
04 (1.28-3.24) .001 1.6 (0.98-2.6) .08
28 (1.38-3.77) 1.74 (0.99-3.06)
47 (0.9-2.4) .135 1.72 (1.03-2.87) .09
06 (0.63-1.8) 1.5 (0.84-2.68)
71 (0.48-1.05) .081 0.8 (0.53-1.21) .27
12 (1.35-3.34) .004 1.95 (1.21-3.15) .01
75 (1.1-2.79) 1.7 (1.01-2.85)
07 (0.47-2.47)
55 (0.98-2.47) .047 1.45 (0.88-2.37) .16
83 (1.13-2.95) 1.6 (0.95-2.72)
99 (0.43-2.31)
03 (0.66-1.63) .266 1.04 (0.63-1.73) .47
89 (0.54-1.48) 1.02 (0.57-1.8)
23 (0.03-1.76) 0.28 (0.03-2.2)
66 (0.3-1.47) 0.43 (0.05-3.48)
Base
nsensus.odel
H
2.
3.
1.
2.
1.
1.
0.
0.
1.
1.
2.
2.
1.
1.
0.
2.
1.
1.
1.
1.
0.
1.
0.
0.
0.● Presence of diabetes (type I and type II together)
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● Smoking status (current, former, never)
Overall survival by each of these factors is shown in Figs
2, A to G, and Fig 2, H shows the survival by randomized
treatment on the same scale for a comparison.
In the univariate analysis, current smokers had survival
Fig 2. Survival by baseline covariates of (A) stratificatio
index, (D) age group, (E), diabetes (F) creatinine level,
time from randomization in years.similar to nonsmokers, and exsmokers had poorer survival.In the multivariate analysis, however, the association was as
expected, with current smokers and exsmokers both having
worse survival than nonsmokers.
The time dependence of each of the covariates over the
follow-up time was checked in themultivariate model using
a test for the correlation of the weighted residuals with time.6
) below knee Bollinger angiogram score, (C) body mass
smoking, and (H) randomized treatment. The x axis isn, (B
(G)TheBollinger above knee angiogramscorewas theonly factor to
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false-positive result given the large number of effects examined.
The effect of randomized treatment on survival.
The significant survival advantage, after 2 years, for patients
randomized to BSX can be seen in Fig 2, H. The opposite
is true in the earlier period, although this difference was not
significant. For the whole follow-up period, the test for a
time-dependent hazard was significant at P  .028.6
As reported elsewhere, this suggests that the clinical deci-
sion about whether a patient should receive BSX or BAP as
first-line treatment for SLI should be informed, at least in part,
by that patient’s likelihood of surviving for2 years.2,3
Compared with the effect of the other baseline covari-
ates, the effect of randomized treatment on survival up to 2
years is small. For that reason, the randomization groupwas
excluded from the prognostic model.
Relationship between the survival to 2 years and
baseline clinical factors (Weibull parametric regression).
The data collected at baseline were examined to determine
if there were any other factors that could improve the
predictive model in addition to those already described.
Four further factors were selected; namely:
1. Number of ankle pressure measurements obtained (please see
below)
2. The maximum ankle pressure obtained (when available)
3. History of MI or angina
4. History of stroke or TIA
The latter two were selected because they were the
Fig 3. Overall survival to 2 years by additional predicto
history of cerebrovascular disease, and (D) history of s
Myocardial infarction; TIA, transient ischemic attack.conditions that affected a substantial proportion of patientsand a priori were expected to affect survival. As was to be
expected in this patient group, an examination of baseline
ankle pressures in the trial leg showed many cases where
one or more of the three possible ankle pressures (dorsalis
pedis, posterior tibial, and perforating peroneal) were
classed as “not detectable.” We postulated that the number
of detectable ankle signals might be a useful (novel) marker,
in addition to actual ankle pressure (whose measurement
can sometimes be difficult in these patients), of disease
burden and thus outcome, including survival.
The original randomization stratification was based on
using a dichotomy of maximum ankle pressure 50 mm
Hg and 50 mm Hg, with those cases where no pressure
could be measured at any of the three sites classed as 50
mm Hg. However, as was described, a careful examination
of the data showed that additional information could be
gleaned in terms number of measurements that were pos-
sible and the actual value of the pressure obtained. In other
words, the number of ankle signals detected—not just the
maximum pressure—was highly predictive of mortality.
These insights and data led us to replace the random-
ization stratification ankle pressure group (50 vs50mm
Hg) with the number of detectable ankle pressures and the
highest ankle pressure. To retain the information in the
stratification groups (Table II), we introduced a separate
code for presence of tissue loss vs rest or night pain only.
Fig 3, A illustrates the survival out to 2 years by the
number of ankle measurements obtained. The highest an-
kle pressure was strongly related to the number of measures
(A) number of ankle pressures, (B) ankle pressure, (C)
. The x axis is time from randomization in years. MI,rs of
trokeobtained (Table III). Survival by highest ankle pressure for
21
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measured, and survival by the presence of a history of
MI/angina or stroke/TIA, or both, are shown, respec-
tively, in Figs 3 B, C, and D.
The variables that were candidates for inclusion in the
predictive model were the four new measures described
above, those listed in Table II excluding the BASIL ran-
domization stratification groupings, which were replaced as
described above, and the TASC and Bollinger above knee
angiography scores, which were omitted in order to have
only one angiographic score (the below knee Bollinger
angiogram score which was the most predictive) in the
model.5
Development of training and validation data sets.
A training data set was selected that consisted of a random
selection of 75% of the original data (339 cases), leaving the
other 113 cases to form a validation data set. When the data
set is not very large, the choice of which proportions to use
in training and validation data sets can be difficult. A
training set with too few cases may yield a poor prediction,
and a validation data set with too few cases may make the
interpretation of the validation results difficult. We decided
that the former was more important and thus selected a
larger training data set. Starting with all the variables men-
tioned above, we attempted to find a simpler model that
might fit the data better. To do this, we used backward
elimination with the option to remove any variables for
which the grouped P value (for categories) was.1. How-
ever, each case was considered in terms of the plausibility of
the coefficients for the individual groups and retained if
these seemed clinically reasonable and important. Contin-
uous variables replaced groupings where effects appeared
linear.
By following this process, we arrived at a final Weibull
model that differed from the full model in that:
● Age was fitted as a continuous variable (range, 39-99 years in
the BASIL cohort).
● The highest ankle pressure (for those with at least one value)
was also fitted as a continuous variable. Although this was not
significant in the final model, we retained it because it con-
tributed in the expected direction and is widely used in
everyday practice. The value of ankle pressure was set to zero
when no signal was detected. This choice does not affect the
fitted values because the number of ankle measurements
Table III. Number of ankle pressures measurable by high
Variable 100 75-
Ankle pressures measurable, No.
None 0
One 12
Two 31
All three 16
All 59 1detected was also included in the model.● The below knee Bollinger scores were simplified to an mean
value of 5 or 5.
● Diabetes was no longer predictive once all the other variables
were included and was omitted from the model.
The coefficients in the linear predictor for the training data
set and the full data set are given in Table IV.
Validation of theWeibull model. When data are used
to select a model, the predictions will tend to be too extreme.
We can correct for this by shrinking the individual predictions
towards the mean. A very reasonable approximation to an
appropriate shrinkage can be obtained by calculating a shrink-
age factor.7 This is calculated as {[1–(df-2)]/k}, where df is
the residual degrees of freedom used in fitting the model and
k is the overall value of the 2 statistic for the final model. The
linear predictors are then shrunk toward the mean value for
the linear predictor by this factor. For this example, a shrink-
age factor of about 0.75 is obtained. We can then check how
well this shrinkage factor will correct any over-fitting by ex-
amining the fit obtained for the validation model.
Linear predictors for the fittedmodel were obtained for
the training and validation data sets, and in each case, three
equally sized groups were formed to make high, medium,
and low groups. Fig 4, A compares the modelled survival
for the three groups based on the training data with the
empirical survival curves. The closeness of the observed and
predicted survival curves indicates that the fit is excellent.
As we would expect, the fit is poorer for the smaller
validation data set; in particular, it is too “optimistic” for
the groups with good survival (Fig 4, B). The shrunken
estimates (Fig 4, C) correct this. Although they appear to
under-fit the poor prediction group, this could just be a
chance effect due to the small size of the prediction data set.
Thus we recommend the shrunken predictor, with a shrink-
age factor of 0.75, to be used for individual predictions.
Using the Weibull model to predict outcomes for
future individual patients. The information in Table IV
can be used to calculate an individual linear predictor for any
combination of covariates. Although the model was devel-
oped and validated from the training data set, it would seem
sensible to make predictions for future patients from all the
data available. This linear predictor can then be shrunk toward
themean of the all the predictors, which has a value of 2.53 for
prediction from the full data.The2.53figure is themean value
nkle pressure obtained
est ankle pressure (mm Hg)
All50-75 0-50 NA
0 0 75 75
56 52 0 153
57 24 0 183
7 1 0 41
120 77 75 452est a
High
100
0
33
71
17of the linear predictor for all the patients in the cohort. The
s coul
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sion coefficients in Table III and the patient’s baseline char-
acteristics. The formula for the shrunken predictor then be-
comes [(2.53  0.75)  (linear predictor 	 2.53)]. The
probability of surviving to any time up to 2 years from the
decision point can then be readily calculated from theWeibull
survival function with a shape parameter of 0.696. Fig 5 is a
histogram of this predicted probability for all 452 patients in
the BASIL trial cohort.
To facilitate access to this tool should clinicians be
interested in exploring it, we developed an Excel spread
sheet (Microsoft, Richmond, Wash) that will be available
for use by logging on to the BASIL trial Web site (http://
basiltrial.com). A screen shot from this resource is illus-
trated in Fig 6. Table V illustrates the shrunken predicted
survival probabilities for several hypothetic cases.
DISCUSSION
Reasons for undertaking the predictive analyses.
The aim of the BASIL trial was to determine whether, in
patients requiring revascularization because of SLI due to
infrainguinal arterial disease, a BSX-first or a BAP-first
Table IV. Fitted linear predictor for the Weibull model (p
From
Coefficie
Intercept 7.517
Tissue loss present 	1.007
Serum creatinine (mol/l)
Low (under 88) 	0.721
High (over 115) 	0.554
Missing 	0.950
(BASE Medium [88-115])
Age (per year) 	0.040
Below knee Bollinger score
5 or over 	0.576
Missing 	0.326
(BASE  under 5)
Smoking
Ex smoker 	0.994
Smoker 	0.783
(BASE  Never smoked)
BMI
Underweight (20) 	0.708
Overweight (25) 0.006
Obese (30) 1.433
Missing 	0.127
(BASE  desirable [20-25])
Number of ankle pressure measurements possible
One 	0.373
Two 0.503
All three 0.655
(BASE  None)
History of MI or angina 	0.878
History of stroke or TIA 	0.581
Highest ankle pressure (mm Hg)* 0.008
log(1/Shape factor) 0.450
Shape factor 0.637
MI, Myocardial infarction; TIA, transient ischemic attack.
*Note that highest ankle pressure is set to zero if no ankle pressure readingrevascularization strategy was associated with a better out-come in terms of AFS, OS, HRQOL, and use of hospital
resources. An intention-to-treat analysis of randomized
data censored in 2008 when 50% of patients had been
monitored for 5 years confirmed that in patients who
survive for 2 years after intervention, initial randomization
to BSX was associated with a significant improvement of
about 7 months in subsequent OS and a nonsignificant
improvement of about 6 months in subsequent AFS. Hav-
ing been presented with these data, the BASIL trial partic-
ipants, as well as surgeons and interventionalists frommany
other countries, urged the trial investigators to construct a
survival model that could help them judge which of their
SLI patients might be likely to survive for2 years and this
enjoy the apparent longer term benefits of BSX.
The current article describes the development of a tool
designed to estimate the chances of a BASIL-like SLI
patient being alive 2 years after randomization. Although
predicting HRQOL, functional status, patency, the quality
of revascularization, and the risks of other major events
such as amputation are important,8-10 we here confined
ourselves to OS during the first 2 years. We did so because,
according to the BASIL outcome data, being alive at 2 years
ve coefficients indicate better survival)
ning data (n  339) From full data (n  452)
SE p Coefficient SE p
1.9591 0.000 8.0978 1.6526 0.000
0.4965 0.042 	0.8022 0.3765 0.033
0.4442 0.105 	0.8176 0.3672 0.026
0.4448 0.213 	0.7579 0.3582 0.034
0.8279 0.251 	0.9773 0.7357 0.184
0.0223 0.071 	0.0493 0.0184 0.007
0.4173 0.167 	0.4798 0.3231 0.138
0.7343 0.656 	0.0529 0.6113 0.931
0.4623 0.032 	1.0895 0.3766 0.004
0.5259 0.136 	0.8427 0.4220 0.046
0.5109 0.165 	0.5839 0.3997 0.144
0.4431 0.989 0.0247 0.3644 0.946
0.7347 0.051 0.7739 0.5280 0.143
0.4611 0.782 	0.2181 0.3479 0.531
0.6237 0.02 	0.2598 0.4829 0.008
0.6987 F-test 0.4233 0.5634 F test
1.0380 0.7943 0.8245
0.3706 0.018 	0.7451 0.2814 0.008
0.3755 0.122 	0.5666 0.2996 0.059
0.0075 0.247 0.0066 0.0060 0.269
0.095 0.001 0.364 0.082 0.001
0.6949
d be obtained.ositi
trai
nt
3
6
1
0
8
2
1
9
0
8
6
3
6
4
1
0
8
1
0
6
6appears to be the key factor that determines whether pa-
JOURNAL OF VASCULAR SURGERY
May Supplement 201060S Bradbury et altients are best served by a BSX-first or BAP-first revascular-
ization strategy.We are well aware of themethodologic and
Fig 4. Fits to the (A) training and (B) validation data set
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fittedWeibull survival for the average linear predictor in e
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analysis in particular confirm that, almost regardless of what
revascularization treatment is offered, outcomes for AFS
and OS are poor in patients with SLI. Thus, at the end of
follow-up, slightly more than one-third of the patients were
alive without major limb amputation of the trial leg, and
less than one-half were still alive. Although most amputa-
tions and deaths occurred in the first year after randomiza-
tion, the high event rate continued at between 10% and
20% per survivor-year thereafter. It is salutary to remember
the form of revascularization a SLI patient receives from his
or her surgeon or interventionalist appears to have a rather
modest overall effect on outcome. The conclusion to be
drawn from this is that the real key to improving the health
of the nation as far as SLI is concerned lies primarily with
better public health, early diagnosis, and aggressive best
medical therapy, and probably not in the operating room or
the interventional suite.
Previous attempts to predict outcomes in SLI.
Many different groups of researchers have attempted to
create models and scoring systems that will accurately pre-
dict individual patient outcomes after vascular interven-
tions.11,12 It is argued that used across different health
economies, such tools may:
● allow important clinical decisions to be made in a more
scientific manner,
● improve the process of obtaining informed consent from
patients,
● mitigate against medicolegal activity,
● allow a fair comparison of the performance of different clini-
cians and hospitals in the context of differing case-mix, and
● improve cost-effectiveness and value for money thus protect-
ing patients, private health care providers, and the tax payer.
Efforts to create such tools are fraught with method-
Fig 5. Probability of surviving to 2 years from randomization
(shrunken estimate) for the 452 patients entered into the BASIL
trial.ologic difficulties, however, and many surgeons and inter-ventionalists choose not to use them. Instead, they prefer to
rely on experience and intuition when making important
clinical decisions about whether—and how—to treat their
patients, including those with SLI. Although we do not
want to devalue experience or the “art” of medicine, the
problem with such an approach is that same patient may be
offered a wide variety of different treatments depending on
the clinician and institution he or she attends.13,14 This
non-evidence-based variability in practice appears increas-
ingly out of step with a respectable body of medical opin-
ion. In the UK, for example, routine submission of detailed
“score-able” prognostic patient data to the National Vas-
cular Database for the purposes of comparative weighted
outcomes analyses is increasingly viewed as a sine qua non
of reasonable, defensible practice.12
As discussed above, although the present data confirm
that all SLI patients are high risk, these patients actually
represent an extremely heterogeneous group in their risks
of death, limb loss, and other major cardiovascular events
over different time horizons.2,3 As others have observed,
this complicates clinical decision making,15 especially when
trying balance short-term risks with longer-term durability
in individuals who could reasonably be treated by either
BSX or BAP.16 The same sort of trade-offs may pertain to
other vascular conditions such as aortic aneurysm (open vs
endovascular aneurysm repair) and carotid artery disease
(surgery vs stenting).
Many previous groups have used observational, non-
randomized data to predict various outcomes after inter-
ventions for SLI, and a small selection of the largest and
most recent studies are briefly summarized here. Investiga-
tors who studied 4000 patients undergoing vein and
prosthetic lower limb bypass in100 Veterans Affairs (VA)
hospitals in the United States were able to stratify the risks
of major amputation and death during a median follow-up
of 44 months. They concluded that risk indices derived
from the preoperative workup may be useful to clinicians in
assessing and communicating risks and prognosis, and that
risk-adjustment of outcomes is critical for evaluating future
therapies in such patients.17 Low cardiac ejection fraction
predicted a significantly shortened 2-year survival after
infrainguinal arterial reconstruction and a trend toward
increased perioperative major adverse clinical events.18
In a large series of diabetic patients undergoing saphe-
nous vein grafts for lower limb ischemia, investigators
reported that they could predict 100%mortality at amedian
of 4 years follow-up by using just four factors.19
Within the Project of Ex-vivo Vein Graft Engineering
via Transfection (PREVENT) III cohort of 1404 patients
undergoing infrainguinal vein bypass surgery for CLI, a
parsimonious risk stratification model (PIII risk score) re-
liably identified a category of CLI patients with a 50%
chance of death or major amputation at 1 year.15
Going forward, the hope is that the application of
these, and perhaps the BASIL risk scoring system, may
result in patients with a poor prognosis being spared the
risk, morbidity, and cost of such BSX, and perhaps being
offered BAP or conservative treatment instead.
I, My
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we choose the baseline variables to examine? Why we did
not use other variables such as functional status, socioeco-
nomic status, cultural factors, medical therapy, and race and
ethnicity, which some may consider equally, perhaps more,
important? There is an almost limitless set of data that one
could try to collect on every SLI patient due to undergo
revascularization in an attempt to predict with perfect
accuracy the likely outcomes for each possible treatment
methodology. This is logistically and ethically impossible.
Furthermore, from a scientific viewpoint, such a “fishing
exercise” is likely to demonstrate very nicely the law of
diminishing returns as the data collected will become in-
creasingly confounded and its collection per se will perturb,
perhaps adversely, the true baseline state of the patient;
thus, some selection and discretion must be exercised.19
Clinicians have told us that they want a survival model
based on robust (objective) baseline variables that are easily
Use menus or en
Notes Patient character
  Tissue loss 
  BMI 
  Creatinine 
  Lower Bollinger S
Enter 40 if below 40 and 95 if over 95  Age 
 Smoking 
Any history of 
MI/angina 
Any history of 
stroke/TIA 
Ankle pressure measurements 
attempted at Dorsal pedis or Posterior 
tibial  and perforating peroneal 
Number of ankle 
pressures measur
Enter 0 if no ankle pressures obtained Ankle Pressure (hobtained in mmHg
Fig 6. Screen shot from prediction spreadsheet. M
Table V. Predicted 6 month, 1 and 2 year survival for 5 p
parametric survival model
Characteristics of 5 BASIL patients with varying predicted 1 and 2
A
Smoking status Ex-smoker Ex-s
BMI Desirable range Ove
Serum creatinine Low Low
Tissue loss? Yes Yes
Number of ankle pressures detected None One
Highest ankle pressure 0
Below knee Bollinger score 5 or more miss
History MI/angina? Yes No
History stroke/TIA? No No
Age (years) 79
6 months 71
1 year 57
2years 40and widely available in day-to-day clinical practice at thepoint of clinical decision making with respect to pursuing a
BSX-first or BAP-first strategy for their patients. When the
BASIL trial was designed in 1997 and 1998, we discussed
at length (as all trialists do) what information should be
collected at baseline and during follow-up. Collect too little
and readers may consider that the trial patients have been
inadequately reported, leading to a lack of confidence in the
trial outcomes. Collect too much, however, and the data
quality and completeness will inevitably deteriorate and
prompt accusations of “fishing.”
The problem with considering racial, social, economic,
and cultural factors in any prediction model is that they are
difficult to define for the purposes of scientific reporting
and do not travel well across national borders. For example,
certain baseline variables, such as race,10 socioeconomic
class, and educational attainment,20,21 that may be consid-
ered important in parts of the world with different health
lues in blue cells to describe the case of interest 
Results 
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low 1 year 57% 
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where the population affected by peripheral arterial disease
(SLI) is largely white and where all citizens are granted
equal access to high-quality free health care and education
at the point of delivery funded through general taxation.
The reviewers have asked us to specifically discuss the
question of race and how that might affect the epidemiol-
ogy of SLI, outcomes from lower limb interventions, and
the appropriateness of generalizing the BASIL trial results
and predictive modelling to other parts of the world. Al-
though with a growing and ageing nonwhite population
this may well change in the future, the UK population
presenting to the National Health Service with SLI for
revascularization is currently largely (90%) white, a statis-
tic reflected in the BASIL trial cohort.22,23 The question is
whether this limits the usefulness of the BASIL trial and the
current modelling in much of the rest of the world where
this may not be the case.
Studies aimed at examining the links between race and
ethnicity and the epidemiology and health outcomes from
PAD, including SLI, are bedevilled with methodologic
problems; perhaps not surprisingly, therefore, the resulting
data are inconsistent and conflicting.20,22,23 Some reports
have found no effect for race after adjusting for social class
and educational attainment,21 whereas others have found
ethnicity is a strong and independent risk factor for PAD
that is not explained by higher levels of diabetes, hyperten-
sion, and body mass index.24
Some have suggested that African American status has a
negative affect on the long-term outcome of infrapopliteal
revascularization, regardless of disease stage or associated
risk factors.25 Further, it has been hypothesized that such
patients are biologically different in a way, as yet unknown,
that may adversely affect the results of lower limb vein
bypass.10
Whether for socioeconomic or biologic reasons, or
both, data from the United States do appear to show a
striking continuing difference in health care outcomes for
white and African American citizens affected by PAD.26-28
A critical analysis of the literature shows that the data on
racial, social, economic, and cultural factors in these pa-
tients are limited methodologically and that the conclu-
sions, even apparently from within a single country such as
the United States, are conflicting and largely unexplained
to everyone’s satisfaction.
Much of the predictive power of socioeconomic factors
on cardiovascular diseases operates through other factors
like smoking and pre-existing disease, which are already in
our model. However, great care must be taken when con-
sidering outcomes reported in observational case series and
controlled trials, such as BASIL, whose cohorts may not
reflect the nature of the unmet need in any particular
country, especially where universal health care coverage is
not offered.
The reviewers have asked us to specifically discuss the
low level of medical therapy observed in the BASIL trial,
the effect of that on outcomes (especially survival), and why
we did not include statin use, for example, in our predictivemodel. It is certainly the case that we previously reported
disappointingly low levels of best medical therapy being
implemented in patients at the time of randomization into
the BASIL trial.2 One would like to think that this simply
reflects the study recruitment period and represents a his-
torical problem, now largely resolved. Regrettably, how-
ever, similar levels of under-treatment in PAD patients have
been reported in recent large, prospective studies con-
ducted in centers of excellence within wealthy countries
with very well funded health care systems.29-31
The question is whether one should include different
levels of best medical therapy into the prediction model. It
seems clear that statin use, for example, is associated with
decreased cardiovascular mortality30,32 and amputation
risk33 in SLI patients. However, we took the view that
because there is overwhelming level 1 evidence that every
SLI patient should be considered for antiplatelet agents and
lipid-lowering therapy—and the great majority should be
taking these agents—regardless of baseline cholesterol,34
we should not include these in our model. We are aware
that others may take a different view, and that in the future,
newer classes of drugsmay also be shown to improve overall
outcomes from lower limb revascularization.35
In summary, using only a small number of readily
available unambiguous and clearly definable baseline clini-
cal and anatomic (angiographic) variables rather than a
large number of variables, many of which are highly sub-
jective, we have been able to stratify risk of death over 1 and
2 years within the BASIL cohort. Importantly, the current
modelling presented here is the only one to be derived from
data collected within the confines of an RCT comparing
BSX and BAP. The factors included in the model were
extremely strong predictors of outcome. Although the
other factors discussed above might possibly be influential,
we think it unlikely that they would add much to what is
already a highly predictive model. Scoring systems popu-
lated with variables that are reproducible across time and
geography are perhaps more likely to be useful and used
beyond narrow parochial boundaries.
Factors predictive of survival in the current model
The factors that were the most important predictors of
BASIL trial patient survival were as follows:
Age, history of MI or stroke, and tissue loss. It is
widely reported that older patients, especially those aged
80 years, are more likely to suffer complications and
poorer outcomes after endovascular36 and surgical inter-
ventions for lower limb ischemia. The fact that significant
previous cardiovascular and cerebrovascular disease and the
presence of ischemic tissue loss rather than only ischemic
rest pain portends a poor survival is not unexpected.37
Ankle pressure and number of detectable ankle
pressures. We have been asked by the reviewers to com-
ment specifically on a number of aspects of this part of our
analysis.
What about abnormally high ankle pressures? Although
we are aware of epidemiologic data showing that an abnor-
mally high ankle pressure and pressure index (1.4) may
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this in an exploratory analysis that divided the ankle pres-
sure data into groups. This observation may not, therefore,
be transferable from population (often screening) studies
(where it presumably reflects vessel incompressibility and
may be a surrogate marker for diabetes, which was of course
included in our model) to patients with SLI, very few of
whom are likely to exhibit such high pressures. It is impor-
tant not to extrapolate the analysis and interpretation of the
current data beyond the boundaries of the trial; they only
apply to patients randomized in BASIL and patients like
them. We have data on preintervention and postinterven-
tion ankle pressures and pressure indices. These are cur-
rently being analyzed and will be reported in a further
separate article in due course.
Why was ankle pressure not significant in the final
model? The reason why ankle pressure was not significant
in the final model is because it is correlated with the number
of ankle measurements obtained. However, as we have
explained, ankle pressure did add a little to the final model
and in the direction expected, although not meeting the
formal requirement for a significant effect. Statistical re-
search suggests that a minimum value of P  .05 may be
too strict for deciding on which predictors to include in a
prognostic model. We also believe that a model that did not
include ankle pressure might be difficult for clinicians to
appreciate and that it was preferable to include it.
Could the authors perform a subgroup analysis of pa-
tients with true CLI (ie, those who meet either the Euro-
pean or Society of Vascular Surgery Rutherford classifica-
tion of CLI)? We could, but we did not think it was helpful
or necessary. Our modelling already takes into account
ankle pressures and can be equally well applied to those
with and without “true” CLI based on a cutoff of 50 mm
Hg. This cutoff is somewhat arbitrary: Why not 45 or 55 or
60 mm Hg? We believe that the ankle pressure metric is
better used as a continuous variable.
We also know that measuring ankle pressures accu-
rately in these patients is difficult and associated with
high levels of interobserver and intraobserver error that
may take a patient’s value alternately above and below
the 50 mm Hg threshold.38 Does that means they have
limb-threatening CLI today but not tomorrow? Obvi-
ously not, and this may be why we found the number of
ankle pressures was a better predictor than the highest
ankle pressure. It is important to point out that the
unique property of the BASIL trial, which sets it apart
from all other studies in the field, is that the data are
randomized. This means that there were same propor-
tion of patients with tissue loss, and the same proportion
patients with ankle pressures  50 mm Hg, in each
group.
Serum creatinine. It is widely recognized and re-
ported that even moderate impairment of renal function, as
quantified, for example, by serum creatinine39 or estimated
glomerular filtration rate,40 independently predicts in mor-
tality in vascular patients whether or not they undergo
dialysis.28,41-43Smoking. It is no surprise that continued smoking
predicts a poor outcome in these patients. Smoking histo-
ries are notoriously unreliable, however, and we did not
supplement self-reported smoking status with objective
testing.37,44
Body mass index. We have found excess mortality in
underweight individuals. This observation, termed the
“obesity paradox,” has been reported before in vascular
patients and is thought to be possibly explained by an
over-representation of individuals with moderate-to-severe
chronic obstructive pulmonary disease (COPD) or other
chronic disease.45 Others have found that despite a higher
rate of perioperative technical difficulties and morbidity
(especially wound infections), obese patients undergoing
lower extremity arterial revascularizations have similar
long-term patency, limb salvage, and survival rates as nono-
bese patients.46
Below knee Bollinger angiogram score. Research
shows increasing severity of lower limb disease, as measured
by ankle pressures and the ankle-brachial pressure index, is
associated with increasing mortality, regardless of whether
the patients have symptomatic lower limb disease. The
anatomic and hemodynamic burden of disease also affects
outcomes after surgical and endovascular lower limb
interventions.5,47
Diabetes. It is widely, although not universally, re-
ported that diabetic patients fare less well in terms of AFS
and OS after surgical and endovascular interventions for
lower limb ischemia.19,28,45-47 This may be at least partly
because diabetic patients present with more advanced and
distal (tibial) disease that reduces run-off.48 Although the
presence of diabetes was significant in the univariate Cox
model, it was not significant in the multivariate model and
was not included in the final Weibull model. At first this
seems counterintuitive. However, we have to ask why dia-
betes is a marker for poor outcomes in patients undergoing
peripheral vascular interventions. Is it the diabetes per se, or
as suggested above, is it the type of lower limb arterial
disease that tends to develop in diabetic patients? We also
have to recognize that a significant proportion of nondia-
betic patients also present with a difficult-to-treat distal and
typically heavily calcified disease. It is perhaps not surprising
then that if one enters factors into a model that accurately
reflect this disease severity (number of ankle pressures
detectable, highest ankle pressure, Bollinger below knee
angiographic scoring), they will (as we have shown here) be
more powerful predictors of survival than diabetic status
per se.49,50
Issues of selection, generalizability, and applicabi-
lity. One of the criticismsmost frequently levelled at RCTs
is their perceived lack of generalizability because of how the
patients are selected for entry. The BASIL trial is no excep-
tion. Because, as requested by clinicians, we have tried to
develop a predictive model that might be useful outside of
the confines of the BASIL trial, the reviewers have quite
rightly strongly challenged us on this issue and requested
that we deal with it robustly. We are very pleased to be
given the opportunity to do so.
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investigators do not accept the premise that the BASIL trial
patients have been “highly selected” in the pejorative sense
of the term and that this selectivity undermines the validity
of the trial findings.3 It is clear that every RCT has to select
patients in the sense that only those patients for whom the
treatment options on offer are appropriate can be invited to
participate. Thus, BASIL is emphatically not a trial of all
patients with SLI any more than other RCTs have been a
study of all aneurysms, or all carotid artery disease, or all
claudicant patients, for example. Rather, BASIL is a trial of
those SLI patients whose disease is due to infrainguinal
disease, who require immediate or early revascularization,
and in whom the responsible surgeons and interventional-
ists determined there was a “gray area of equipoise” on the
best manner in which to achieve that revascularization. This
is the “uncertainty principle” that underpins all RCTs and
makes them possible. Not to “select” in this way would be
unethical and highly inappropriate scientifically.
This paradigm has been the bedrock upon which all
other major vascular surgical and interventional trials have
been built, and BASIL is no different. Thus, the landmark
trials of interventions for carotid disease, aneurysms, and
claudication did not randomize every patient with the
condition but only those in whom there was reasonable
doubt about what was best for the patient.
By conducting and publishing the BASIL audit data in
2005, we believe we provided considerably more informa-
tion than most other reports on how the patients random-
ized were numerated from the denominator of all patients
presenting with SLI due to infrainguinal disease.2 Specifi-
cally, about one-third of all patients presenting to the 27
participating hospitals with SLI due to infrainguinal disease
andwho required immediate or early revascularization were
considered to be in the “gray area of clinical equipoise”
with respect to the relative merits of a BSX-first vs a BAP-
first strategy for revascularization.
Given the often entrenched views on this issue that are
found in the literature and quantified in the Delphi consen-
sus studies undertaken as a prelude to the BASIL trial,12,13
this was in reality a surprisingly (pleasingly) high propor-
tion. All of these patients were invited to enter the trial, and
about 70% agreed. Given the nature of the patients and
their condition, we think this is an impressively high pro-
portion that compares very favorably with other landmark
vascular trials. That so many patients were randomized and
that most underwent the assigned treatment in a timely
manner reflect great credit on the teams in each of the
participating hospitals.
Lastly, in reporting the BASIL trial outcomes, we
have attempted to describe in as much detail as possible
the clinical and anatomic (angiographic) characteristics
of the patients randomized.5 We hope that by doing so
readers will be able to make informed judgments about
what extent their patients are either similar to or dissim-
ilar from those randomized in BASIL and decide to use
or not use the trial data and modelling accordingly as
part of their decision making practice.How might the modelling be used in clinical prac-
tice? The results presented here have tried to meet a clear
and present demand from fellow physicians for a clinically
useful survival-prediction tool based on the BASIL data.
We have presented a method of predicting survival for the
type of patients in the BASIL trial using clinical and ana-
tomic (angiographic) baseline factors, all of which are easily
obtainable in routine clinical practice. Notwithstanding
the important issues of generalizability and the consid-
erable methodologic and interpretational difficulties in-
herent in these sorts of analyses discussed above, the
specific intention here is to give clinicians an idea of how
long an individual patient (similar to those randomized
in BASIL) might live. The clinician can choose to use
that information along with other data to counsel the
patient, reach a decision about what treatment might be
best, and take informed consent.
If the model suggests that the patient only has a 10%
chance of being alive at 2 years, then BASIL suggests that a
BSX-first strategy is not justified because of the associated
increased morbidity and costs. Rather, the appropriate
choice would seem to be BAP, or as one reviewer sug-
gested, perhaps primary amputation or symptomatic best
medical and nursing treatment only. However, if the model
predicts a 90% chance that the patient will be alive at 2
years, then the BASIL trial data suggest that a BSX-first
strategy is preferable because the patient will probably
survive to enjoy the longer-term benefits of BSX in terms of
AFS and OS at no significant additional cost.
If themodel predicts a 50/50 chance of the patient being
alive in 2 years, then that is helpful also. In this case the
decision whether to attempt BSX or BAP can reasonably
decided on other factors, for example, relative availability of
institutional expertise with the two techniques, cost, and
importantly, patient choice, based on a full discussion of the
likely medical journey the patient will take after each of the
two strategies as described in theBASIL trial clinical outcomes
reports. Used properly, as suggested above, we think our
model is a useful tool in the clinician’s armamentarium.
With regard to validation, BASIL is the only RCT to
examine this issue and this is the only survival model based
on level 1 data. We would be delighted if others were to
make the brave commitment to undertake further RCTs in
this field and help validate—or not, as the case may be—
our findings.
In reality, we and probably many others tend to make
these sorts of everyday but very important clinical judge-
ments about our SLI patients on the basis of no level 1
evidence; we have to because there is not much such
evidence. Although not wishing to entirely dismiss the
“art” of medicine, the problem is that experience and
intuition lead different clinicians to make very different
decisions. We see that phenomenon every day in our hos-
pitals and we quantified it in our Delphi consensus papers as
a prelude to BASIL. Notwithstanding the considerable
difficulties of so doing, with BASILwe are trying to take the
decision regarding the choice of surgery or angioplasty
when there is true uncertainty forward by applying at least
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methods or conclusions; we invite such colleagues to do the
further randomized studies that are clearly needed.
Lastly, as alluded to by one of our reviewers, we can also
use this type of prediction methodology to define the
characteristics of a group of patients whose outcomes are so
poor, regardless of what method is used to try to revascu-
larize their leg, that they would probably be better served
by amputation or medical (symptomatic) treatment only.
The question of how to identify and manage these patients
will be the subject of a further separate report.
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McCarter, A. Reid, Glasgow Royal Infirmary (1); S.
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Houston,Ninewells Hospital, Dundee (1); M. Armon, J.Clarke, J. Cockburn, J. Colin, S. Girling, S. Scott-Barrett,
P. Wilson, Y. Wilson, *Norfolk & Norwich Hospital
(60); J. Beard, T. Cleveland, P. Chan, P. Gaines, R.
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